KEGG   DRUG: Dupilumab
Entry
D10354                      Drug                                   
Name
Dupilumab (USAN/INN);
Dupilumab (genetical recombination) (JAN);
Dupixent (TN)
Product
Formula
C6512H10066N1730O2052S46
Exact mass
146806.3649
Mol weight
146896.9522
Sequence
(Heavy chain)
EVQLVESGGG LEQPGGSLRL SCAGSGFTFR DYAMTWVRQA PGKGLEWVSS ISGSGGNTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR LSITIRPRYY GLDVWGQGTT
VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS
RWQEGNVFSC SVMHEALHNH YTQKSLSLSL G
(Light chain)
DIVMTQSPLS LPVTPGEPAS ISCRSSQSLL YSIGYNYLDW YLQKSGQSPQ LLIYLGSNRA
SGVPDRFSGS GSGTDFTLKI SRVEAEDVGF YYCMQALQTP YTFGQGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H139-L219, H152-H208, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'139-L'219, H'152-H'208, H'266-H'326, H'372-H'430, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Dermatological agent
 DG03243  Atopic dermatitis agent
Remark
Therapeutic category: 4490
ATC code: D11AH05
Product: D10354<JP/US>
Efficacy
Anti-inflammatory, Anti-IL-4/IL-13 antibody
  Disease
Atopic dermatitis [DS:H01358]
Asthma [DS:H00079]
  Type
Monoclonal antibody
Target
IL4R (CD124) [HSA:3566] [KO:K05071]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04151  PI3K-Akt signaling pathway
hsa04630  JAK-STAT signaling pathway
hsa04640  Hematopoietic cell lineage
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 D DERMATOLOGICALS
  D11 OTHER DERMATOLOGICAL PREPARATIONS
   D11A OTHER DERMATOLOGICAL PREPARATIONS
    D11AH Agents for dermatitis, excluding corticosteroids
     D11AH05 Dupilumab
      D10354  Dupilumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Dupilumab
     D10354  Dupilumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  44  Allergic agents
   449  Miscellaneous
    4490  Miscellaneous
     D10354  Dupilumab (USAN/INN); Dupilumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10354  Dupilumab
 Dermatological agent
  DG03243  Atopic dermatitis agent
   D10354  Dupilumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10354  Dupilumab
 Dermatological agent
  DG03243  Atopic dermatitis agent
   D10354  Dupilumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL4R (CD124)
     D10354  Dupilumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10354
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10354
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10354
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10354
Other DBs
CAS: 1190264-60-8
PubChem: 172232447
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system